Hepatocellular Carcinoma
Conditions
Keywords
chimeric antigen receptor T cell (CAR- T), glypican-3 (GPC3), hepatocellular carcinoma (HCC)
Brief summary
Patients with hepatocellular carcinoma (a type of primary liver cancers) are enrolls in this study. The cancer has progressed after standard treatment, or the patient cannot receive regular treatment. Investigator made a gene called chimeric antigen receptor derived from an antibody that recognizes Glypican 3, a protein detected in in a large proportion of hepatocellular carcinoma. The gene will introduce into T cell from patient's blood to make them recognize and kill cancer cells. The aim of this study is to evaluate the efficacy, tolerance and safety of chimeric antigen receptor-modified T (CAR-T) cell targeting Glypican 3 for advanced hepatocellular carcinoma.
Interventions
BIOLOGICALCAR-T cell immunotherapy
Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows: Dose 1: 1x10\^7/m2 Dose 2: 3x10\^7/m2 Dose 3: 1x10\^8/m2 The cell numbers are calculated according to CAR-positive T cells.
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
1. GPC3 positive HCC, tumor size \>= 5 cm, cannot receive standard treatment, Expected survival time\>=3 months. 2. Routine blood test: white blood cell count（WBC)\>= 2.5×10\^9/L, hemoglobin (Hb)\>= 9.0 g/dL, blood platelet \>= 60×10\^9/L, Lymphocyte percentage\>=15%. 3. Blood biochemical parameters: ALB \>= 30 g/L, ALT \<= 5 times of the normal value, AST \<= 5 times of the normal value, serum lipase\<=1.5 times of the normal value, serum amylase\<=1.5 times of the normal value， total bilirubin \<= 2.5 times of the normal value. 4. Prothrombin time INR \< 1.7. 5. Ejection fraction (EF) \>= 55%, oxygen saturation (SO2) \> 90%. 6. No allergic reaction to contrast material. 7. Karnofsky score \>= 60%. 8. Child-puge score \<7. 9. Peripheral venous access. 10. Voluntarily signed informed consent.
Exclusion criteria
1. Pregnancy or lactation. 2. Systemic steroid treatment ( \>prednisone equivalent/kg/day). 3. Patients with previous history of cell immunotherapy or antibody therapy. 4. Patients received radiotherapy/chemotherapy in the past 4 weeks. 5. Patients are participating in other clinical trials. 6. Patients with uncontrolled symptoms including infection, heart failure, arrhythmia. 7. Patients with acute allergic reaction. 8. History of liver transplantation. 9. Patients with anticoagulant treatment. 10. Patients with hepatic encephalopathy. 11. Eligible for hepatectomy, liver transplantation or other standard treatment. 12. Unstable gastrointestinal and respiratory bleeding. 13. Active viral, fungal or bacterial infections. 14. Heart failure classification (NYHA): II-IV. 15. Patients are unable or unwilling to comply with the requirements of the study protocol. 16. Patients do not meet the criteria above.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patient with dose limiting toxicity | 2 months | After each dose of T cell infusion, the adverse effects related to T cell therapy such as fever and jaundice are observed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiological evaluation of tumor size after CAR- T immunotherapy | 3 months | Evaluate the therapeutic effect of CAR-T immunotherapy radiological observation of the tumor size after infusion of CAR-T cells. |
| Peripheral tumor marker | 3 months | After CAR-T cell infusion, alpha fetoprotein (AFP) will be tested regularly in blood. |
| Number of Peripheral CAR-T cell | 3 months | The number and proliferation in vivo are tested with Flow Cytometry regularly. |
Countries
China
Contacts
Primary ContactDecai Yu, MD
Backup ContactWenfang Tian, PhD
Outcome results
None listed